(Total Views: 246)
Posted On: 10/26/2022 5:21:50 PM
Post# of 63
It has been over six months since BNTX paid almost $4 million for the exclusive rights to do a deal with MNTB to use its lipid nano crystal delivery platform for BNTX's mRNA drugs.
If the parties had decided to terminate this agreement, one or both would have presumably issued a press release.
Rather, today, at the Think conference, JJ confirmed this deal was still alive, and he hoped to close it, along with an agreement for MAT 2203, by the end of 2022.
My guess is that BNTX and MTNB are working on a really big deal that takes time to construct, and that potential partners are reviewing the data on the ENACT trial, given the stellar results announced to date.
If I am reading the tea leaves correctly, this could be a very happy new year for MTNB and its shareholders.
If the parties had decided to terminate this agreement, one or both would have presumably issued a press release.
Rather, today, at the Think conference, JJ confirmed this deal was still alive, and he hoped to close it, along with an agreement for MAT 2203, by the end of 2022.
My guess is that BNTX and MTNB are working on a really big deal that takes time to construct, and that potential partners are reviewing the data on the ENACT trial, given the stellar results announced to date.
If I am reading the tea leaves correctly, this could be a very happy new year for MTNB and its shareholders.
(1)
(0)
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
